In vitro activity of ertapenem against strains isolated from diabetic foot infections

Médecine et maladies infectieuses
A SottoJ-P Lavigne

Abstract

The authors aimed to evaluate the in vitro activity of ertapenem against bacterial strains isolated from diabetic foot infections (DFI). All diabetic patients hospitalized for a first episode of DFI (stages 2 to 4, according to the International Working Group of Diabetic Foot Classification) were selected in the Nîmes University hospital between January 2005 to December 2005. MICs were determined using both E-test strips and dilution methods on bacterial strains isolated from foot samples. Two hundred and fifty-two bacteria (154 Gram-positive cocci including 94 Staphylococcus aureus, 80 Gram-negative bacilli with 56 Enterobacteriaceae, and 18 anaerobes) were studied. Ertapenem was active against all Streptococcus spp., Enterobacteriaceae, anaerobes, and also against 89.8% of methicillin-susceptible S. aureus isolates. However, this antibiotic was active only against 31.5% of Staphylococcus epidermidis, 21.8% of Enterococcus faecalis, and 15.8% of Pseudomonas aeruginosa. Our results indicate that ertapenem may be a useful agent to treat patients suffering from DFI after bacterial identification.

References

Oct 8, 1999·Diabetic Medicine : a Journal of the British Diabetic Association·N TentolourisA J Boulton
Oct 31, 2000·Diabetes/metabolism Research and Reviews·B A Lipsky, A R Berendt
May 17, 2001·Antimicrobial Agents and Chemotherapy·D M LivermoreD L Shungu
Jan 5, 2002·Expert Opinion on Investigational Drugs·I Odenholt
Feb 13, 2003·Diabetic Medicine : a Journal of the British Diabetic Association·C N DangE B Jude
Mar 22, 2003·Diabetic Medicine : a Journal of the British Diabetic Association·Y GeK Holroyd
Jun 24, 2004·Diabetic Medicine : a Journal of the British Diabetic Association·A Hartemann-HeurtierA Grimaldi
Aug 19, 2004·Diabetic Medicine : a Journal of the British Diabetic Association·F Game, W Jeffcoate
Oct 9, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Benjamin A LipskyUNKNOWN Infectious Diseases Society of America
Nov 18, 2005·Lancet·Andrew J M BoultonJan Apelqvist
Nov 30, 2005·European Journal of Internal Medicine·E M ShankarA R Usha
Jan 31, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·N TentolourisN Katsilambros
Jan 24, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lawrence A LaveryBenjamin A Lipsky
Aug 31, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F DrobniewskiUNKNOWN Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis of the European Committee for Antimicrobi

❮ Previous
Next ❯

Citations

May 4, 2011·World Journal of Diabetes·Jean-Louis RichardJean-Philippe Lavigne

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.